[Clinical research on sequential dual-drug nonspecific immunotherapy in patients with hepatocellular carcinoma]
Zhonghua Gan Zang Bing Za Zhi
.
2018 Apr 20;26(4):313-315.
doi: 10.3760/cma.j.issn.1007-3418.2018.04.016.
[Article in Chinese]
Authors
J P Zhou
1
,
S Y Yao
2
,
Y Y Chen
2
,
Z J Mo
3
,
Y T Tang
2
,
Y Q Zhou
2
,
C M Xu
4
,
T Q Liu
2
Affiliations
1
Department of General Surgery, The First People's Hospital of Qinzhou, Guangxi Qinzhou 535000, China.
2
Department of Hepatobilliary Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
3
Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
4
Department of Ultrasound, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
PMID:
29996346
DOI:
10.3760/cma.j.issn.1007-3418.2018.04.016
No abstract available
Keywords:
Carcinoma, hepatocellular; Hepatectomy; Interleukin-2; Thymalfasin; immunotherapy.